Unilens Vision Inc. (OTC Bulletin Board: UVICF; TSX Venture Exchange: UVI), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today announced the launch of the all new monthly C-VUE Advanced® Toric Multifocal. The C-VUE Advanced Toric Multifocal for astigmatic presbyopes will be sold directly to independent eye care professionals offering technology so sophisticated, it will allow for complete customization including the capability to specify the ADD power and zone size. The monthly replacement lens features a free trial program, advanced hydration material and exceptional deliverability (typically ships within 2 to 3 days).
C-VUE Advanced Toric Multifocal is available in new convenient blister packaging with hioxifilcon D, a material which offers advanced hydration properties that allow it to retain 97% of its moisture resulting in all day comfort. As the presbyopic population continues to grow faster than the population as a whole, this new product offering (for astigmatic presbyopes) and free trial program will provide independent practitioners with an additional specialty C-VUE contact lens option that contributes to patient retention and practice profitability.
C-VUE Advanced Toric Multifocal is an easy to fit specialty toric multifocal contact lens, designed in an extremely wide range of customizable parameters with exceptional deliverability. The lens offers made to order base curves, diameters, powers and cylinders combined with axis in one degree steps. Practitioners can even specify individual ADD powers and zone sizes.
"The launch of the C-VUE Advanced Toric Multifocal continues our time honored tradition of providing outstanding specialty lens technology exclusively to licensed optical professionals," stated Michael Pecora, Chief Executive Officer of Unilens Vision Inc. "With our Free Trial Program and 120-day performance guarantee, we eliminate the time and expense of returning lenses, thereby increasing profitability to the Independent Eye Care Professional as well," concluded Mr. Pecora.
Pitt researchers uncover mechanisms behind uveal melanoma resistance